Institutional members access full text with Ovid®

Chitosan-based Dressing for the Treatment of External/Accessible Bleedings in Children With Bleeding Tendency

Misgav, Mudi MD; Kenet, Gili MD; Martinowitz, Uriel MD

Journal of Pediatric Hematology/Oncology: March 2014 - Volume 36 - Issue 2 - p 140–142
doi: 10.1097/MPH.0b013e31828ac8b6
Original Articles

Introduction: Bleeding episodes in patients with congenital or acquired bleeding disorders are usually managed with factor concentrates or blood products. However, external and accessible bleeds may effectively be managed with topical hemostasis.

Materials and Methods: After the application of the Hemcon, a Food and Drug Administration-approved chitosan-based hemostatic dressing was used as the “last resort” to successfully control external bleeds in 2 patients with severe bleeding disorders. We describe a single-center experience with this dressing, including its use in pediatric patients as the first mode of therapy.

Results: A total of 5 patients (median age 2 y) with severe bleeding disorders were treated with topical chitosan-based dressing for a total of 6 bleeding episodes. The dressing was used either after the failure of extensive systemic therapy or as the first choice of treatment. In 4 of the 6 episodes, bleeding ceased immediately alleviating the need for systemic therapy. There was no rebleeding after the removal of the dressing and no adverse events or local skin reactions were recorded.

Conclusion: Hemostatic dressings, such as the chitosan, should be encouraged for the treatment of external/accessible bleeds, especially among the pediatric patients with bleeding tendency.

National Hemophilia Center & Center of Thrombosis, The Chaim Sheba Medical Center, Tel-Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Israel

The authors declare no conflict of interest.

Reprints: Mudi Misgav, MD, The National Hemophilia Center & Center of Thrombosis, The Chaim Sheba Medical Center, Tel-Hashomer, Sackler Faculty of Medicine, Tel Aviv University, 52621 Israel (e-mail: mudi.misgav@sheba.health.gov.il).

Received September 28, 2012

Accepted January 30, 2013

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.